The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Genzyme; Roche; Sanofi; Shire; Tesaro
Consulting or Advisory Role - Baxalta; Celgene; H3 Biomedicine; Quantum Design Europe; Shire
Speakers' Bureau - Celgene; Sanofi; Shire
Research Funding - Agios; ASLAN Pharmaceuticals; AstraZeneca; Bayer; BeiGene; Celgene; Genentech; Halozyme; Immunomedics; Lilly; Merrimack; Millennium; Novartis; Novocure; OncoMed; Pfizer; Pharmacyclics; Roche
Travel, Accommodations, Expenses - Bayer; H3 Biomedicine; Merck; Sanofi
A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
 
Davide Melisi
Consulting or Advisory Role - Baxter; Evotec; Incyte; Lilly; Shire
Research Funding - Celgene; Evotec; Incyte; Shire
Travel, Accommodations, Expenses - Celgene
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Lilly; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Genentech/Roche; Merck Serono; Novartis; Taiho Pharmaceutical
Research Funding - Array BioPharma; AstraZeneca; Green Cross; Lilly; Novartis
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - International Cancer Consultants; Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; BeiGene; Novartis; START
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Anna M. Varghese
Consulting or Advisory Role - Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Erkut Hasan Borazanci
Consulting or Advisory Role - Biogen (I); Corcep; Fujifilm; Genzyme (I); Ipsen; Novartis (I); Teva (I)
Speakers' Bureau - Biogen (I); Genentech (I); Genzyme (I); Ipsen; Novartis (I); Taiho Pharmaceutical; Teva (I)
Research Funding - Ambry Genetics (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Idera (Inst); Lilly (Inst); MabVax (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst); Samumed (Inst)
 
Teresa Macarulla Mercade
No Relationships to Disclose
 
Francesca Simionato
No Relationships to Disclose
 
Joon Oh Park
Consulting or Advisory Role - Celgene; Merck Serono; Shire
Speakers' Bureau - Celgene
Research Funding - Celgene
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Rgenix (Inst); Sanofi (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Sandrine J. Faivre
Honoraria - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Ipsen; Lilly; Merck Serono; MSD; Novartis
Consulting or Advisory Role - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Ipsen; Lilly; Merck Serono; MSD; Novartis
Research Funding - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Ipsen; Lilly; Merck Serono; MSD; Novartis
Travel, Accommodations, Expenses - Bayer; Blueprint Medicines; Bristol-Myers Squibb; Ipsen; Lilly; Merck Serono; MSD; Novartis
 
Yumin Zhao
No Relationships to Disclose
 
Ivelina Gueorguieva
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Michael Man
Employment - Lilly
Stock and Other Ownership Interests - Lilly; Pfizer
 
Shawn Estrem
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Karim Adnane Benhadji
Employment - Lilly; Taiho Pharmaceutical
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Lilly
 
Mark Lanasa
Employment - AstraZeneca; Immunocore
Stock and Other Ownership Interests - AstraZeneca
 
Susan C. Guba
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
Travel, Accommodations, Expenses - Lilly
 
Rocio Garcia-Carbonero
Honoraria - Advanced Accelerator Applications; AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Gilead Sciences (I); Ipsen; Lilly (I); Merck; Merck (I); Novartis; Pfizer; PharmaMar; PharmaMar (I); Roche; Roche (I); Sanofi; SERVIER; SERVIER (I); Sysmex (I)
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Novartis; Pfizer
Speakers' Bureau - Ipsen; Pfizer
Research Funding - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer
Travel, Accommodations, Expenses - Merck; Roche